FG-3246 Phase II trial advances with 36% PSA50 response in monotherapy.
Kyntra Bio, Inc. Common Stock (KYNB) News
Latest headlines that mention KYNB, newest first · each headline opens the original publisher
- Last price
- $4.50
- Day change
- -1.75%
- Next earnings
- 2026-11-09
KYNB headlines
latest coverageNot much coverage yet. KYNB has appeared in only a few headlines lately; new stories show up here as publishers cover it.
Image source: The Motley Fool. May 11, 2026 Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
KYNB news alerts
Get an alert by email or push when a new headline mentions KYNB.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.